靶向B细胞的CAR-T细胞疗法激活患者及非人灵长类体内的CD8+细胞毒性CARneg旁观者T细胞
本研究对非人灵长类(NHP)和患者来源的T细胞进行单细胞RNA测序,以识别靶向B细胞的CAR-T细胞治疗后CARneg旁观者T细胞激活的表型和转录组特征。在可高度转化的CD20 CAR NHP模型中,观察到CAR-T细胞扩增期间出现一群独特的活化CD8+ CARneg T细胞;在替沙来塞输注后的患者中也鉴定出转录相似的细胞群。机制研究显示IL-2和IL-15以剂量依赖方式诱导旁观者样CD8+ T细胞,体外活化的及患者来源的具有旁观者表型的T细胞通过不依赖T细胞受体的机制有效杀伤白血病细胞。
要点
- 靶向B细胞的CAR-T细胞治疗后,NHP模型和患者中均出现活化CD8+ CARneg旁观者T细胞。
- 该群细胞上调NK细胞标志物(KIR3DL2、CD160、KLRD1)、趋化因子及受体(CCL5、XCL1、CCR9),下调初始T细胞相关基因(SELL、CD28)。
- IL-2和IL-15以剂量依赖方式诱导旁观者样CD8+ T细胞,后者通过不依赖TCR的机制杀伤白血病细胞。
核心结论
- 据作者所知,这些数据首次全面鉴定并描述了靶向B细胞的CAR-T细胞治疗后CARneg旁观者CD8+ T细胞,提示CAR-T细胞输注可能通过新机制触发增强的抗白血病反应。
研究设计与样本
- 研究对非人灵长类(NHP)和患者来源的T细胞进行单细胞RNA测序,患者样本来自试验#NCT03369353(ClinicalTrials.gov注册)。
- 使用可高度转化的CD20 CAR NHP模型,并在替沙来塞输注后的患者中鉴定转录相似细胞群。
- 进行机制研究,检测IL-2和IL-15暴露对旁观者样CD8+ T细胞诱导的影响,并开展体外杀伤实验。
主要发现
- 在CD20 CAR NHP模型中,CAR-T细胞扩增期间出现一群独特的活化CD8+ CARneg T细胞。
- 该群CD8+ CARneg T细胞上调NK细胞标志物(KIR3DL2、CD160、KLRD1)、趋化因子及受体(CCL5、XCL1、CCR9),下调初始T细胞相关基因(SELL、CD28)。
- 在替沙来塞输注后的患者中鉴定出转录相似的细胞群。
- IL-2和IL-15暴露以剂量依赖方式诱导旁观者样CD8+ T细胞。
- 体外活化的及患者来源的具有旁观者表型的T细胞通过不依赖T细胞受体的机制有效杀伤白血病细胞。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cells hold promise as a therapy for B-cell-derived malignancies, and despite their impressive initial response rates, a significant proportion of patients ultimately experience relapse. Although recent studies have explored the mechanisms of in vivo CAR T-cell function, little is understood about the activation of surrounding CARneg bystander T cells and their potential to enhance tumor responses. We performed single-cell RNA sequencing on nonhuman primate (NHP) and patient-derived T cells to identify the phenotypic and transcriptomic hallmarks of bystander activation of CARneg T cells following B-cell-targeted CAR T-cell therapy. Using a highly translatable CD20 CAR NHP model, we observed a distinct population of activated CD8+ CARneg T cells emerging during CAR T-cell expansion. These bystander CD8+ CARneg T cells exhibited a unique transcriptional signature with upregulation of natural killer-cell markers (KIR3DL2, CD160, and KLRD1), chemokines, and chemokine receptors (CCL5, XCL1, and CCR9), and downregulation of naïve T-cell-associated genes (SELL and CD28). A transcriptionally similar population was identified in patients after a tisagenlecleucel infusion. Mechanistic studies revealed that interleukin-2 (IL-2) and IL-15 exposure induced bystander-like CD8+ T cells in a dose-dependent manner. In vitro activated and patient-derived T cells with a bystander phenotype efficiently killed leukemic cells through a T-cell receptor-independent mechanism. Collectively, to our knowledge, these data provide the first comprehensive identification and profiling of CARneg bystander CD8+ T cells following B-cell-targeting CAR T-cell therapy and suggest a novel mechanism through which CAR T-cell infusion might trigger enhanced antileukemic responses. Patient samples were obtained from the trial #NCT03369353, registered at www.ClinicalTrials.gov.
引用
- Kaminski J, Fleming RA, Alvarez-Calderon F, et al. B-cell-directed CAR T-cell therapy activates CD8+ cytotoxic CARneg bystander T cells in patients and nonhuman primates. Blood. 2024. PMID: 38558106. doi:10.1182/blood.2023022717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。